Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Interplay between PI3K/mTOR Signaling and IRE1a-XBP1 Promotes Survival of Pre-B NRAS G12D all Cells Providing a Therapeutic Vulnerability for the "Undruggable" Driver RAS

Iris Appelmann, MD, Azam Salimi, Michael Huber, PhD, Mirle Schemionek, PhD, Margherita Vieri, PhD, Tim H Brümmendorf, MD, John B. Patterson, Behzad Kharabi Masouleh, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140299

Published: 2020

Journal Articles

Critical Interferon-Response Genes Are Induced By JAK2 V617F but Repressed By BCR-ABL, and They Are Responsible for the Differential Effects of Interferon in PV Vs. CML

Claudia Schubert, Ivan G. Costa, Mirle Schemionek, PhD, Kristina Feldberg, Julian Baumeister, Tim H. Brümmendorf, MD, Steffen Koschmieder, Nicolas Chatain

Blood (2017) 130 (Supplement 1): 4226.

https://doi.org/10.1182/blood.V130.Suppl_1.4226.4226

Published: 2017

Journal Articles

Bcr-Abl1 Kinase-Independent Upregulation of FcγRIIb Mediates Malignant Signaling That Is Critical for Leukemogenesis

Oliver Herrmann, Msc, Samantha Langer, Caroline Wessling, Michael Huber, PhD, Shaoguang Li, MD PhD, Tim Henrik Bruemmendorf, Steffen Koschmieder, Mirle Schemionek, PhD

Blood (2017) 130 (Supplement 1): 2862.

https://doi.org/10.1182/blood.V130.Suppl_1.2862.2862

Published: 2017

Journal Articles

Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8 + and CD4 + T Cell-Epitopes for Immunotherapeutic Approaches

Tatjana Bilich, Annika Nelde, Daniel J. Kowalewski, Janet Peper, Mirle Schemionek, PhD, Lothar Kanz, MD, Helmut R. Salih, MD, Tim H. Brümmendorf, MD, Vladan Vucinic, MD, Dietger Niederwieser, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD, Juliane S. Stickel, MD

Blood (2016) 128 (22): 4232.

https://doi.org/10.1182/blood.V128.22.4232.4232

Published: 2016

Journal Articles

Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase

Anne-Sophie Bouillon, Monica S. Ferreira, PhD, Shady Adnan Awad, Johan Richter, MD, Henrik Hjorth-Hansen, MD PhD, Thoas Fioretos, Sebastian Hummel, Mirle Schemionek, PhD, Satu Mustjoki, MD PhD, Fabian Beier, MD, Tim H. Brümmendorf, MD

Blood (2016) 128 (22): 4243.

https://doi.org/10.1182/blood.V128.22.4243.4243

Published: 2016

Journal Articles

Elucidation of Additional Mutations By Next-Generation Sequencing Is of Clinical Significance in Patients with Rare MPNs and MDS/MPN Overlap Syndromes

Martin MJ Kirschner, MD, Mirle Schemionek, PhD, Matthias Begemann, PhD, Susanne Isfort, MD, Kristina Feldberg, Tim H. Brümmendorf, MD, Steffen Koschmieder, MD

Blood (2016) 128 (22): 4260.

https://doi.org/10.1182/blood.V128.22.4260.4260

Published: 2016

Journal Articles

HLA Ligandome Analysis of Different Hematological Malignancies Identifies a Small Panel of "Pan-Leukemia"-Associated Antigens

Linus Backert, Daniel J. Kowalewski, Simon D. Walz, Heiko Schuster, Claudia Berlin, Mirle Schemionek, PhD, Tim H. Brümmendorf, MD, Vladan Vucinic, MD, Dietger Niederwieser, MD, Lothar Kanz, MD, Helmut R. Salih, MD, Katja Weisel, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD, Juliane S. Stickel, MD

Blood (2016) 128 (22): 2169.

https://doi.org/10.1182/blood.V128.22.2169.2169

Published: 2016

Journal Articles

Dasatinib Exerts Differential Effects on Normal and BCR-ABL Positive Hematopoietic Cells in a Transgenic Mouse Model of Chronic Phase-CML

Claudia Schubert, Msc, Nicolas Chatain, PhD, Till Braunschweig, MD, Mirle Schemionek, PhD, Kristina Feldberg, Melanie Hoffmann, Tim H. Brümmendorf, MD, Satu Mustjoki, MD PhD, Olli Dufva, Steffen Koschmieder, MD

Blood (2016) 128 (22): 1885.

https://doi.org/10.1182/blood.V128.22.1885.1885

Published: 2016

Journal Articles

A Novel TNF-Alpha Antibody Based Therapeutic Approach to Target Leukemic Stem Cells in Bcr-Abl Disease

Oliver Herrmann, Msc, Claudia Schubert, Msc, Tom Luedde, MD PhD, Till Braunschweig, MD, Steffen Koschmieder, MD, Tim H Brümmendorf, MD, Mirle Schemionek, PhD

Blood (2015) 126 (23): 15.

https://doi.org/10.1182/blood.V126.23.15.15

Published: 2015

Journal Articles

Genetic Depletion of Fc Gamma Receptor 2b Affects CML Stem Cell Biology

Oliver Herrmann, MSc, Caroline CA Weßling, MD, Michael Huber, PhD, Shaoguang Li, MD PhD, Tim H. Brümmendorf, MD, Steffen Koschmieder, MD, Mirle Schemionek, PhD

Blood (2014) 124 (21): 4528.

https://doi.org/10.1182/blood.V124.21.4528.4528

Published: 2014

Journal Articles

Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.

Mirle Schemionek, PhD, Ulrich Steidl, MD, PhD, Albrecht Schwab, MD, Daniel G Tenen, MD, Copland Mhairi, PhD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Christian Preisinger, PhD, Carsten Mueller-Tidow, MD, Tim H Brümmendorf, Steffen Koschmieder, MD

Blood (2012) 120 (21): 2776.

https://doi.org/10.1182/blood.V120.21.2776.2776

Published: 2012

Journal Articles

Genomic Instability in CML-CP originates From the Most Primitive Imatinib-Refractory Leukemia Stem Cells

Elisabeth Bolton, Mirle Schemionek, PhD, Hans-Urlich Klein, Grazyna Hoser, PhD, Sylwia Flis, Thoralf Lange, Linda Kerstiens, Margaret Nieborowska-Skorska, MD, PhD, Martin C. Müller, MD, Hardik Modi, Ravi Bhatia, MD, Steffen Koschmieder, MD, Tomasz Skorski, MD, PhD

Blood (2012) 120 (21): 909.

https://doi.org/10.1182/blood.V120.21.909.909

Published: 2012

Journal Articles

Differential Activity of Pazopanib and Imatinib Against PDGFRA-Related MPN and AML

Steffen Koschmieder, MD, Mirle Schemionek, PhD, Christian Elling, PhD, Utz Krug, MD, Torsten Kessler, MD, Wolfgang E. Berdel, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 5153.

https://doi.org/10.1182/blood.V118.21.5153.5153

Published: 2011

Journal Articles

Genomic Instability Originates From Leukemia Stem Cells in a Mouse Model of CML-CP

Elisabeth Bolton, Mirle Schemionek, PhD, Hans-Ulrich Klein, Linda Kerstiens, Steffen Koschmieder, MD, Tomasz Skorski, MD, PhD

Blood (2011) 118 (21): 445.

https://doi.org/10.1182/blood.V118.21.445.445

Published: 2011

Journal Articles

Novel PDGFRA Point Mutations in Hypereosinophilic Syndrome Induce Growth Factor Independence and Leukemia in Vitro and In Vivo.

Christian Elling, Philipp Erben, MD, Christoph Walz, MD, Marie Frickenhaus, Mirle Schemionek, PhD, Martin Stehling, PhD, Hubert Serve, MD, PhD, Nick C.P. Cross, PhD, Wolfgang Berdel, MD, Carsten Mueller-Tidow, MD, Andreas Reiter, MD, Steffen Koschmieder, MD

Blood (2009) 114 (22): 767.

https://doi.org/10.1182/blood.V114.22.767.767

Published: 2009

NARROW

Interplay between PI3K/mTOR Signaling and IRE1a-XBP1 Promotes Survival of Pre-B NRAS G12D all Cells Providing a Therapeutic Vulnerability for the "Undruggable" Driver RAS

Critical Interferon-Response Genes Are Induced By JAK2 V617F but Repressed By BCR-ABL, and They Are Responsible for the Differential Effects of Interferon in PV Vs. CML

Bcr-Abl1 Kinase-Independent Upregulation of FcγRIIb Mediates Malignant Signaling That Is Critical for Leukemogenesis

Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8 + and CD4 + T Cell-Epitopes for Immunotherapeutic Approaches

Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase

Elucidation of Additional Mutations By Next-Generation Sequencing Is of Clinical Significance in Patients with Rare MPNs and MDS/MPN Overlap Syndromes

HLA Ligandome Analysis of Different Hematological Malignancies Identifies a Small Panel of "Pan-Leukemia"-Associated Antigens

Dasatinib Exerts Differential Effects on Normal and BCR-ABL Positive Hematopoietic Cells in a Transgenic Mouse Model of Chronic Phase-CML

A Novel TNF-Alpha Antibody Based Therapeutic Approach to Target Leukemic Stem Cells in Bcr-Abl Disease

Genetic Depletion of Fc Gamma Receptor 2b Affects CML Stem Cell Biology

Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.

Genomic Instability in CML-CP originates From the Most Primitive Imatinib-Refractory Leukemia Stem Cells

Differential Activity of Pazopanib and Imatinib Against PDGFRA-Related MPN and AML

Genomic Instability Originates From Leukemia Stem Cells in a Mouse Model of CML-CP

Novel PDGFRA Point Mutations in Hypereosinophilic Syndrome Induce Growth Factor Independence and Leukemia in Vitro and In Vivo.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only